BHCM
DNLI icon

Brevan Howard Capital Management’s Denali Therapeutics DNLI Stock Holding History

Brevan Howard Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,917
Closed -$365K – 1224
2024
Q4 		$365K Buy
17,917
+6,756
+61% +$173K ﹤0.01% 717
2024
Q3 		$325K Sell
11,161
-18,196
-62% -$451K ﹤0.01% 819
2024
Q2 		$682K Buy
+29,357
New +$564K 0.01% 512

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brevan Howard Capital Management's DNLI Position: Q1 2025 in Review

Brevan Howard Capital Management sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 17,917 shares — an estimated $365K sold.

Brevan Howard Capital Management first reported a position in DNLI in Q2 2024 and held it in 3 quarters. The position peaked at $682K in Q2 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

  • Brevan Howard Capital Management reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 17,917 Denali Therapeutics shares in Q1 2025, an estimated $365K.
  • Brevan Howard Capital Management first reported a position in Denali Therapeutics in Q2 2024 and held it in 3 quarters.
  • Brevan Howard Capital Management's Denali Therapeutics position peaked at $682K in Q2 2024.
  • 222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Brevan Howard Capital Management's 13F filing for Q1 2025, filed 15 May 2025.